Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation

Azacyclic FTY720 Analogues That Limit Nutrient Transporter Expression but Lack S1P Receptor Activity and Negative Chronotropic Effects Offer a Novel and Effective Strategy to Kill Cancer Cells in Vivo

(2015) Bin Chen et al.   ACS Chemical Biology

Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A

(2015) F. Zonta et al.   BLOOD

ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo

(2015) Rajeswaran Mani et al.   EXPERIMENTAL HEMATOLOGY

Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications

(2014) John Camm et al.   AMERICAN HEART JOURNAL

Sphingosine-1-phosphate receptor 1 reporter mice reveal receptor activation sites in vivo

(2014) Mari Kono et al.   JOURNAL OF CLINICAL INVESTIGATION

Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity

(2014) R Pippa et al.   LEUKEMIA

Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides

(2014) Kıvanç Birsoy et al.   NATURE

Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory

(2014) Nitai C Hait et al.   NATURE NEUROSCIENCE

FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors

(2013) Miki Kiyota et al.   APOPTOSIS

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

(2013) Paolo Neviani et al.   JOURNAL OF CLINICAL INVESTIGATION

Structure–Activity Relationships and Molecular Modeling of Sphingosine Kinase Inhibitors

(2013) Dong Jae Baek et al.   JOURNAL OF MEDICINAL CHEMISTRY

Sphingosine Kinase Activity Is Not Required for Tumor Cell Viability

(2013) Karen Rex et al.   PLoS One

Nutrient transporters: the Achilles’ heel of anabolism

(2013) Alison N. McCracken et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Design, Synthesis, and Antileukemic Activity of Stereochemically Defined Constrained Analogues of FTY720 (Gilenya)

(2013) Rebecca Fransson et al.   ACS Medicinal Chemistry Letters

Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1

(2012) Mark E. Schnute et al.   BIOCHEMICAL JOURNAL

The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate

(2012) P Gergely et al.   BRITISH JOURNAL OF PHARMACOLOGY

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis

(2012) Sahar A. Saddoughi et al.   EMBO Molecular Medicine

Autophagy induced by FTY720 promotes apoptosis in U266 cells

(2012) Aijun Liao et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Metabolic trajectory of cellular differentiation in small intestine by Phasor Fluorescence Lifetime Microscopy of NADH

(2012) Chiara Stringari et al.   Scientific Reports

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

(2011) Jeffrey A. Cohen et al.   ANNALS OF NEUROLOGY

FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells

(2011) Craig T. Wallington-Beddoe et al.   Autophagy

Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins

(2011) Kimberly Romero Rosales et al.   BIOCHEMICAL JOURNAL

Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A

(2011) A. Salas et al.   BLOOD

Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma

(2011) Hany A. Omar et al.   HEPATOLOGY

Sphingosine-1-phosphate signaling and its role in disease

(2011) Michael Maceyka et al.   TRENDS IN CELL BIOLOGY

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

(2010) A. Oriol et al.   HAEMATOLOGICA

The Sphingosine 1-Phosphate Transporter, SPNS2, Functions as a Transporter of the Phosphorylated Form of the Immunomodulating Agent FTY720

(2010) Yu Hisano et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Elimination of a Hydroxyl Group in FTY720 Dramatically Improves the Phosphorylation Rate

(2010) E. Jary et al.   MOLECULAR PHARMACOLOGY

Effects of Phosphorylation of Immunomodulatory Agent FTY720 (Fingolimod) on Antiproliferative Activity against Breast and Colon Cancer Cells

(2008) Yasuo Nagaoka et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN